Jefferies Downgrades Allergan (AGN) to Hold
More News related to AGN
- Allergan (AGN) Receives FDA Approval for OZURDEX(TM)
- Allergan Receives FDA Approval for OZURDEX(TM) Biodegradable, Injectable Steroid Implant with Extended Drug Release for Retinal Disease
- Sanofi-Aventis (SNY) On the Prowl For A Mega-Deal In the U.S.?
- SunTrust Initiates Coverage on Several Drug Manufacturers & Suppliers
- Oceana Therapeutics Completes Transaction for Rights to Deflux and Solesta; Company Achieves Key Growth Milestone Despite Challenging Economic Environment
Jefferies downgrades Allergan (NYSE: AGN) from Buy to Hold with a $62 price target.
Allergan, Inc., a multi-specialty healthcare company, discovers, develops, and commercializes specialty pharmaceutical, medical device, and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatological, breast aesthetics, obesity intervention, urological, and other specialty markets worldwide.
Related Categories
DowngradesStocks Mentioned
-21.23Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
